Stem Cells Live: Current and Future Trends in Regenerative Medicine

Challenging opening comments by Greg Bonfiglio to initiate this discussion session with a bang. A series of complications have hit the industry in recent days: failure of the Athersys phase two trial, federal reimbursement for wound healing Apligraf (Organogenesis) cut. The question posed is, ‘where is the industry now and are these events predicative of the future?’ Alain Vertes, Managing …

Stem Cells Live: Why Just Acute Myocardial Infarction?

Dr Michael May, CEO at Centre for Commercialization of Regenerative medicine (CCRM) opened the second day of World Stem Cell and Regenerative medicine Congress with a presentation titled: if You Build it will they come? CCRM was founded in 2011 with the mission to create a hub in Canada for Regenerative Medicine products development and commercialization. More than $20M spent …